Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the broad spectrum antimicrobial herbal extract from P. fruticosa

References

• Atkinson A, Kenny JR, Grime K. (2005). Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 33:1637–1647.
   PubMed Web of Science ®Google Scholar
• Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. (2001). Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 29:30–35.
   PubMed Web of Science ®Google Scholar
• Bailey DG, Malcolm J, Arnold O, Spence JD. (1998). Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101–110.
   PubMed Web of Science ®Google Scholar
• Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A. (2007). Scaling factors for the extrapolation of in vivometabolic drug clearance from in vitrodata: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33–45.
   PubMed Web of Science ®Google Scholar
• Bergeron C, Marston A, Wolfender J-L, Mavi S, Rogers C, Hostettmann K. (1997). Isolation of Polyphenols from Polygala gazensis and Liquid Chromatography–Mass Spectrometry of Related African Polygala Species. Phytochem Analysis 8:32–36.
   Google Scholar
• Chavez ML, Jordan MA, Chavez PI. (2006). Evidence-based drug–herbal interactions. Life Sci 78:2146–2157.
   PubMed Web of Science ®Google Scholar
• Cho US, Park EY, Dong MS, Park BS, Kim K, Kim KH. (2003). Tight-binding inhibition by α-naphthoflavone of human cytochrome P450 1A2. Biochim Biophys Acta 1648:195–202.
   PubMed Web of Science ®Google Scholar
• DeLano WL. (2002). The PyMOL molecular graphics system. http://www.pymol.org.
   Google Scholar
• de Visser SP, Shaik S. (2003). A proton-shuttle mechanism mediated by the porphyrin in benzene hydroxylation by cytochrome p450 enzymes. J Am Chem Soc 125:7413–7424.
   PubMed Web of Science ®Google Scholar
• Fugh-Berman A, Ernst E. (2001). Herb–drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 52:587–595.
   PubMed Web of Science ®Google Scholar
• Fuhr U. (1998). Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 18:251–272.
   PubMed Web of Science ®Google Scholar
• Gelfand M, Mavi S, Drummond RB, Ndemera B. (1985). The Traditional Medical Practitioner in Zimbabwe. Gweru: Mambo Press.
   Google Scholar
• Hostettmann K, Marston A, Ndjoko K, Wolfender JL. (2000). The potential of African plants as a source of drugs. Curr Org Chem 4:973–1010.
   Web of Science ®Google Scholar
• Houston JB, Carlile DJ. (1997). Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891–922.
   PubMed Web of Science ®Google Scholar
• Izzo AA. (2005). Herb–drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 19:1–16.
   PubMed Web of Science ®Google Scholar
• Izzo AA, Ernst E. (2009). Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69:1777–1798.
   PubMed Web of Science ®Google Scholar
• Kiani J, Imam SZ. (2007). Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 6:33.
   PubMedGoogle Scholar
• Klepser TB, Doucette WR, Horton MR, Buys LM, Ernst ME, Ford JK, Hoehns JD, Kautzman HA, Logemann CD, Swegle JM, Ritho M, Klepser ME. (2000). Assessment of patients’ perceptions and beliefs regarding herbal therapies. Pharmacotherapy 20:83–87.
   PubMed Web of Science ®Google Scholar
• Kramer B, Rarey M, Lengauer T. (1999). Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37:228–241.
   PubMed Web of Science ®Google Scholar
• Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. (2006). Hyperforin in St. John’s wort drug interactions. Eur J Clin Pharmacol 62:225–233.
   PubMed Web of Science ®Google Scholar
• Masimirembwa CM, Thompson R, Andersson TB. (2001). In vitro high throughput screening of compounds for favourable metabolic properties in drug discovery. Comb Chem High T Scr 4:245–263.
   PubMed Web of Science ®Google Scholar
• Masimirembwa CM, Bredberg U, Andersson TB. (2003). Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 42:515–528.
   PubMed Web of Science ®Google Scholar
• Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA. (2000). St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500–7502.
   PubMed Web of Science ®Google Scholar
• Mukinda JT, Eagles PF. (2010). Acute and sub-chronic oral toxicity profiles of the aqueous extract of Polygala fruticosa in female mice and rats. J Ethnopharmacol 128:236–240.
   PubMed Web of Science ®Google Scholar
• Paolo ERD, Hamburger MO, Stoeckli-Evans H, Rogers C, Hostettmann K. (1989). New Chromonocoumarin (= 6H, 7H-[1] Benzopyrano[4,3-b][1]benzopyran-6,7-dione) Derivatives from Polygala fruticosa BERG. Helvetica Chimica Acta 72:1455–1462.
   Google Scholar
• Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD, Johnson EF. (2007). Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282:14348–14355.
   PubMed Web of Science ®Google Scholar
• Saxena A, Tripathi KP, Roy S, Khan F, Sharma A. (2008). Pharmacovigilance: effects of herbal components on human drugs interactions involving cytochrome P450. Bioinformation 3:198–204.
   PubMedGoogle Scholar
• Shimada T, Yamazaki H, Foroozesh M, Hopkins NE, Alworth WL, Guengerich FP. (1998). Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol 11:1048–1056.
   PubMed Web of Science ®Google Scholar
• Tarirai C, Viljoen AM, Hamman JH. (2010). Herb–drug pharmacokinetic interactions reviewed. Expert Opin Drug Metab Toxicol 6:1515–1538.
   PubMed Web of Science ®Google Scholar
• Thelingwani RS, Zvada SP, Dolgos H, Ungell AL, Masimirembwa CM. (2009). In vitroand in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug–drug interactions. Drug Metab Dispos 37:1286–1294.
   PubMed Web of Science ®Google Scholar
• Thompson TN. (2000). Early ADME in support of drug discovery: the role of metabolic stability studies. Curr Drug Metab 1:215–241.
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455–461.
   PubMed Web of Science ®Google Scholar
• Watt JM, Breyer-Brandwijk MG. (1962). The Medicinal and Poisonous Plants of Southern and Eastern Africa. Edingburgh and London: Livingstone Ltd.
   Google Scholar
• Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, Tucker GT. (2003). Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433–440.
   PubMed Web of Science ®Google Scholar
• Yang XX, Hu ZP, Duan W, Zhu YZ, Zhou SF. (2006). Drug–herb interactions: eliminating toxicity with hard drug design. Curr Pharm Des 12:4649–4664.
   PubMed Web of Science ®Google Scholar
• Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. (2003). Interactions of herbs with cytochrome P450. Drug Metab Rev 35:35–98.
   PubMed Web of Science ®Google Scholar